Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A, for the Rosiglitazone Clinical Trials Study Group: Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 24:308-315, 2001
The first complete sentence in column 2 on page 309 should state: “LDL cholesterol concentrations were estimated using the Friedewald equation (11) when triglycerides were ≤400 mg/dl.” In line 4, “>400 mg/dl” was corrected to “≤400 mg/dl.”
In lines 12 and 20 in column 1 of Table 2 on page 312, “Baseline triglycerides ≤5.17 mmol/l” should state “Baseline triglycerides ≤2.26 mmol/l.”
The first sentence of paragraph 2 in column 1 on page 312 should state: “In general, the rosiglitazone treatment groups demonstrated small but significant increases in triglyceride levels, with greater increases observed in patients with baseline levels ≤2.26 mmol/l (200 mg/dl); however, these changes were not dosage related.”
In the same paragraph, the third sentence should state: “In patients with baseline triglyceride levels 2.26 mmol/l, no change was significant in any treatment group (Table 2).” In both sentences, “5.17 mmol/l” was corrected to “2.26 mmol/l.”
The third complete sentence of column 3 on page 310 should state: “In comparison with placebo, there were small but statistically significant increases in the rosiglitazone 2 mg b.i.d., 8 mg o.d., and 4 mg b.i.d. treatment groups.” In line 14, the first mention of “4 mg b.i.d.” was corrected to “2 mg b.i.d.”
